StocksMedium•18 November 2026•
1 min read
Hims & Hers Launches Peptides+ Platform for Non-FDA Approved Longevity Treatments
Key Facts
1Hims & Hers Health launched five new peptide and longevity treatments as part of its Peptides+ platform rollout.
2The new treatments include compounded formulations of sermorelin, glutathione, and NAD+, along with vitamin B-12 and L-carnitine.
3The company acknowledged that these compounded formulations are not approved by the FDA.
Hims & Hers Health launched five new peptide and longevity treatments as part of its Peptides+ platform rollout. CNBC reported that the new offerings include compounded formulations of sermorelin, glutathione, and NAD+, along with vitamin B-12 and L-carnitine. The company acknowledged that these compounded formulations are not approved by the FDA.
HIMS closed at $17.55 on November 17, 2026, with the stock trading between a low of $17.14 and a high of $18.7 during that session. The launch represents an expansion of the company's telehealth offerings into the longevity space as it seeks to diversify its product portfolio beyond weight-loss drugs.